The second in our highly speculative Marijuana Stock selection of 2014 is Cannabis Science, Inc. (Stock Symbol: CBIS). CBIS is one of the top performing marijuana penny stocks in 2014 and is selling as of January 28, 2014 for 22 cents. The 52 week high was 26 cents and the low was 3 cents. So it is selling near its one year high.
Cannabis Science, Inc. develops cannabis pharmaceutical products. This company is dedicated to the creation of cannabis-based medicines. It is at the forefront of cannabinoid research and development for unmet medical needs. The company works in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is laying a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for cancer, autism, Influenza, PTSD and other ailments. Cannabis Science was founded on February 29, 1996 and is headquartered in Colorado Springs, CO.
Cannabinoids have an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.
Some applications of cannabinoids have been well established in peer-reviewed literature such as alleviating nausea and stimulating the appetite for people with AIDS and Cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its perceived effectiveness in alleviating certain autoimmune disorders, such as Crohn’s Disease.
The CBIS team of scientists will produce and commercialize products derived from cannabis-based botanical extracts. Even today, new uses for cannabinoids are consistently discovered. For example, scientists recently found that topical cannabinoid-based preparations can be effective against MRSI, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments.
In 2001, an article published in the Canadian Medical Association Journal revealed that, based on self-identified needs, it is estimated that 2% (or 400,000) of Canadian adults were already utilizing cannabinoids for medical purposes. With ever increasing use and scientific support for cannabinoid medicines occurring in the US and around the world, we are looking at a new multi-billion dollar industry that will play a dramatic role that will impact human health on a global scale.
No comments:
Post a Comment